SCHEDULE: Tevogen Inc. Insider Reports Shareholding Update

Kirti Desai amends Schedule 13D to report a restricted stock award of 750,000 shares contingent on achieving $1 billion in revenue.

Summary

• Kirti Desai has filed an amendment to Schedule 13D regarding Tevogen Inc. common stock.
• This filing updates the beneficial ownership information.
• A restricted stock award of 750,000 shares was granted on September 14, 2026.
• These shares vest only if Tevogen Inc. achieves $1 billion in aggregate revenue between September 14, 2026, and September 30, 2031.
• The reporting person now beneficially owns 992,983 shares, representing 6.3% of the class.
• This includes 805,000 restricted shares that carry voting rights but are subject to forfeiture and cannot be sold until vested.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative score due to the conditional nature of the stock award and the lack of new financial performance data.

Positives

• Kirti Desai's beneficial ownership is updated, providing transparency.
• The company has granted a significant number of restricted shares (750,000) to a key individual, potentially aligning incentives.
• The reporting person holds voting power over 992,983 shares, indicating substantial influence.

Negatives

• The 750,000 restricted shares are subject to forfeiture if the $1 billion revenue target is not met within the specified period.
• These restricted shares cannot be sold, transferred, or encumbered prior to vesting.
• The filing does not provide any new financial performance data or operational updates for Tevogen Inc.

Risks

• The primary risk is the failure to achieve the $1 billion revenue target within the performance period, leading to forfeiture of the 750,000 restricted shares.
• There is a risk of misconduct or competitive activities by the reporting person, which could also lead to forfeiture.
• The shares are subject to forfeiture upon termination of service with the company.
• The award may not be assumed in the event of a change in control.

Future Outlook

The future outlook for the restricted stock award is contingent on Tevogen Inc. achieving $1 billion in aggregate revenue between September 14, 2026, and September 30, 2031. Failure to meet this target will result in forfeiture of the award.

Management Comments

• The reporting person has been granted 750,000 shares of restricted Common Stock pursuant to the Restricted Common Stock Award Agreement.
• The RSA Shares will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031.

Industry Context

StockSavvy.ai notes that performance-based restricted stock awards are common in the biotechnology and pharmaceutical sectors, aiming to incentivize management to achieve significant revenue milestones. The $1 billion target suggests ambitious growth expectations for Tevogen Inc.

Related Party Transactions

• Grant of 750,000 restricted shares to Kirti Desai on September 14, 2026, under the Tevogen Inc. 2024 Omnibus Incentive Plan.

Stakeholder Impact

• Shareholders: The conditional nature of the award may indicate management's focus on future growth, but the lack of immediate financial results means no direct impact from this filing alone.
• Management (Kirti Desai): Significant potential upside if revenue targets are met, but also risk of forfeiture.
• Employees: The company's focus on achieving a large revenue target could influence strategic priorities and operational efforts.

Next Steps

• Monitor Tevogen Inc.'s revenue performance against the $1 billion target during the performance period.
• Observe any further amendments to Schedule 13D related to this or other shareholdings.
• Await certification by the Board of Directors regarding revenue achievement for vesting.

Key Dates

Keywords

Tevogen Inc., Schedule 13D, Insider Trading, Restricted Stock Award, Beneficial Ownership, Revenue Target, Vesting Conditions, Corporate Governance